BAIYUNSHAN PH - Announcement of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.’s 2025 annual profit distribution plan and 2026 mid-term cash dividend plan
Overseas regulatory announcement
This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
The full Chinese text of the company's announcement on the profit distribution plan for 2025 and the mid-term cash dividend plan for 2026 published by Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (the "Company") on the website of the Shanghai Stock Exchange (www.sse.com.cn) is hereby published for reference only.
Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
board of directors
Guangzhou, China, March 20, 2026
As at the date of this announcement, the Company’s board of directors includes executive directors Mr. Li Xiaojun, Mr. Chen Jiehui, Mr. Cheng Hongjin, Mr. Tang Heping and Mr. Li Hong, and independent non-executive directors Mr. Chen Yajin, Mr. Huang Min, Mr. Huang Longde and Ms. Sun Baoqing.
Securities code: 600332 Securities abbreviation: Baiyunshan Announcement Number: 2026-015
Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
2025 annual profit distribution plan and
Announcement on the 2026 mid-term cash dividend plan
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
●Annual profit distribution plan for 2025: cash dividend of RMB 0.45 per share (tax included).
●The annual profit distribution in 2025 will be based on the total share capital registered on the equity registration date for the implementation of equity distribution. The specific date will be clarified in the equity distribution implementation announcement. If the company's total share capital changes before the equity registration date for equity distribution, it is planned to maintain the total distribution amount unchanged, adjust the per share distribution ratio accordingly, and will separately announce the specific adjustments.
●The company does not fall into any situation that may be subject to other risk warnings as stipulated in Item (8) of Article 9.8.1, Paragraph 1 of the Shanghai Stock Exchange Stock Listing Rules.
- Profit distribution plan for 2025
(1) Specific contents of the profit distribution plan
As audited by Daxin Accounting Firm (Special General Partnership), as of December 31, 2025, the final undistributed profit in the parent company's statement of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company" or the "Company") was RMB 7,263,234,411.77. According to the resolution of the 33rd meeting of the company's ninth board of directors, the company plans to distribute profits in 2025 based on the total share capital on the equity registration date of the equity distribution. The profit distribution plan is as follows:
The company plans to distribute a cash dividend of RMB 0.45 per share (tax included) to all shareholders. As of December 31, 2025, the company's total share capital was 1,625,790,949 shares, and based on this calculation, a total cash dividend of RMB 731,605,927.05 (tax included) was planned to be distributed. The company's cash dividends for the year (including the interim cash dividend of RMB 650,316,379.60) totaled RMB 1,381,922,306.65, accounting for 46.32% of the net profit attributable to shareholders for the year. There will be no conversion of capital reserve funds into share capital this year.
If the company's total share capital changes between the date of disclosure of this announcement and the equity registration date for equity distribution, the company plans to maintain the total distribution amount unchanged and adjust the per share distribution ratio accordingly. If the total share capital changes subsequently, specific adjustments will be announced separately.
(2) Explanation of whether other risk warning situations are involved
Project Total cash dividends for the current year and the previous year (RMB) 1,381,922,306.65 1,300,632,759.20 1,217,717,420.80 Total repurchase and cancellation (RMB) 0 0 0 Net profit attributable to shareholders of listed companies
2,983,113,594.80 2,835,496,163.51 4,055,678,691.49 profit (RMB)
The parent company's statement at the end of the current year is not distributed.
7,263,234,411.77
Profit (RMB)
Accumulated cash in the last three fiscal years
3,900,272,486.65
Total dividends (RMB)
Cumulative repurchases in the past three fiscal years
Total amount written off (RMB)
Average net profit for the past three fiscal years
3,291,429,483.27
Run (RMB)
Accumulated cash in the last three fiscal years
Total amount of dividends and repurchase cancellation (person 3,900,272,486.65
(RMB Yuan)
Accumulated cash in the last three fiscal years
Is the total amount of dividends and repurchases written off? No?
Less than 50 million yuan
Cash dividend ratio (%) 118.50%
Is the cash dividend ratio less than 30%? No
Whether it touches the Stock Listing Rules
Article 9.8.1 Paragraph 1 (8) No
The provisions of this paragraph may be implemented by other
Risk warning situations
As shown in the table above, the company's cumulative cash dividends and repurchases and write-offs in the past three fiscal years are higher than 30% of the average annual net profit in the past three fiscal years, and it does not trigger the situation that may be subject to other risk warnings as stipulated in Article 9.8.1, Item (8), Paragraph 1, of the Shanghai Stock Exchange Stock Listing Rules.
- Mid-term cash dividend plan for 2026
In order to improve investors' returns and share operating results, in accordance with relevant regulations such as the "Regulatory Guidelines for Listed Companies No. 3 - Cash Dividends of Listed Companies (Revised in 2025)" and in combination with the company's actual conditions, the company plans to formulate a 2026 mid-term profit distribution plan and implement equity distribution within the specified period, provided that the cash dividend conditions are met and the company's normal operations and sustainable development are not affected. The amount of the 2026 mid-term cash dividend will not exceed the net profit attributable to shareholders of the listed company during the corresponding period. In order to simplify the dividend distribution process, the shareholders' meeting is requested to authorize the company's board of directors to formulate and implement an interim dividend plan for 2026, subject to meeting the conditions for cash dividends.
- Decision-making procedures implemented by the company
The company held the 33rd meeting of the ninth board of directors on March 20, 2026, and reviewed and approved the "Proposal on the Company's 2025 Annual Profit Distribution Plan and 2026 Interim Cash Dividend Plan". The distribution plan is in line with the profit distribution policy stipulated in the "Articles of Association" and the company's disclosed shareholder return plan. It was agreed to submit the proposal to the company's shareholders' meeting for review, and agreed to request the shareholders' meeting to authorize the board of directors to formulate and implement interim profit distribution matters.
The "Proposal on the Company's 2025 Profit Distribution Plan and 2026 Interim Cash Dividend Plan" still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
- Related risk warnings
This profit distribution plan takes into account the company's development stage, future capital needs and other factors, and will not have a significant impact on the company's operating cash flow, nor will it affect the company's normal operations and long-term development. This profit distribution plan still needs to be submitted to the company's 2025 annual shareholders' meeting for review and approval before it can be implemented. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
March 20, 2026